Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Advertisement
The goal of PedAL is to establish a data-driven developmental therapeutics program.
The trial's treatment regimen included single-agent dasatinib for the first three months, followed by venetoclax.
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Mice with CML who were given a synthetic version of miR-142 lived much longer and were even cured.
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
Advertisement
The FDA also announced it approved a new capsule dosage form of bosutinib.
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
Researchers reviewed data from 107 patients with CML who developed a T315I mutation in BCR-ABL1.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
In this poor-risk population of patients, 73% responded to the triplet.
A study suggests a rationale for targeting PRMT5 in patients with relapsed or refractory MCL who have high mutation burdens.
The story of The Max Foundation begins with its namesake, Maximiliano “Max” M. Rivarola.
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Countries with a lower sociodemographic index are underrepresented in clinical trials of TKIs for the treatment of CML.
The TKI ponatinib may be the optimal third-line therapy for patients with chronic myeloid leukemia.
Adherence to oral anticancer agents appeared to be good among adults with chronic myeloid leukemia (CML).
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.
With a growing number of treatment options, clinicians need guidance on the best third-line options for patients with CML.
The FDA cleared an Investigational New Drug (IND) application for IkT-001Pro for the treatment of chronic myelogenous ...
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.